BioArctic（BIOA B）株式概要
バイオアークティック社（BioArctic AB）は、スウェーデンで中枢神経系疾患患者向けの生物学的薬剤を開発している。 詳細
BIOA B Community Fair Values
Create NarrativeSee what 30 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
BioArctic AB (publ) 競合他社
価格と性能
| 過去の株価 | |
|---|---|
| 現在の株価 | SEK 300.20 |
| 52週高値 | SEK 364.40 |
| 52週安値 | SEK 192.00 |
| ベータ | -0.67 |
| 1ヶ月の変化 | 0.27% |
| 3ヶ月変化 | -8.92% |
| 1年変化 | 54.74% |
| 3年間の変化 | -1.38% |
| 5年間の変化 | 109.93% |
| IPOからの変化 | 935.17% |
最新ニュース
ナラティブ更新 • Jun 16
BIOA B: Future Returns Will Depend On Sustained NLRP3 Execution Risk
Analysts have maintained their SEK 240.00 price target on BioArctic, citing materially higher modeled revenue growth of 14.61% and a stronger 23.70% profit margin outlook, partly offset by a lower future P/E assumption of 61.02x. Analyst Commentary Recent research around BioArctic highlights a split view between optimism on the long term opportunity and caution on what is already reflected in the share price.
ナラティブ更新 • Jun 01
BIOA B: Alzheimer’s Access Delays And Nordic Rollout Will Shape Future Returns
Analysts now set their fair value estimate for BioArctic at SEK 363, down slightly from SEK 367. This reflects updated assumptions around revenue growth, profit margins and a lower future P/E multiple.Recent updates
ナラティブ更新 • Jun 16
BIOA B: Future Returns Will Depend On Sustained NLRP3 Execution Risk
Analysts have maintained their SEK 240.00 price target on BioArctic, citing materially higher modeled revenue growth of 14.61% and a stronger 23.70% profit margin outlook, partly offset by a lower future P/E assumption of 61.02x. Analyst Commentary Recent research around BioArctic highlights a split view between optimism on the long term opportunity and caution on what is already reflected in the share price.ナラティブ更新 • Jun 01
BIOA B: Alzheimer’s Access Delays And Nordic Rollout Will Shape Future Returns
Analysts now set their fair value estimate for BioArctic at SEK 363, down slightly from SEK 367. This reflects updated assumptions around revenue growth, profit margins and a lower future P/E multiple.分析記事 • May 28
BioArctic's (STO:BIOA B) Soft Earnings Don't Show The Whole Picture
BioArctic AB (publ)'s ( STO:BIOA B ) stock was strong despite it releasing a soft earnings report last week. We think...分析記事 • May 24
BioArctic AB (publ) Just Reported A Surprise Profit, And Analysts Lifted Their Estimates
As you might know, BioArctic AB (publ) ( STO:BIOA B ) recently reported its quarterly numbers. Revenues of 66% beat...ナラティブ更新 • May 18
BIOA B: Future Returns Will Depend On High NLRP3 Execution Risk
Analysts kept their SEK 240.00 price target for BioArctic unchanged, with slightly lower discount rate and profit margin assumptions, and a higher future P/E multiple that reflects refined views on the stock's risk profile and earnings power. Analyst Commentary Recent research on BioArctic has centered on how changing assumptions around risk, profitability, and long term earnings power feed into valuation.ナラティブ更新 • Apr 22
BIOA B: Future Returns Will Depend On High NLRP3 Execution Risk
Analysts have kept their SEK 240.0 price target for BioArctic unchanged, explaining the steady view by slightly adjusting discount rate, revenue growth, profit margin and future P/E assumptions, while balancing higher perceived risk with ongoing optimism around the broader NLRP3 and cardiovascular opportunity highlighted in recent peer research. Analyst Commentary Research coverage around NLRP3-targeted therapies has been active, with several firms updating their views and price targets on peers such as BioAge Labs.
ナラティブ更新 • Apr 08
BIOA B: NLRP3 Opportunity And Alzheimer’s Data Will Shape Balanced Outlook
The analyst fair value estimate for BioArctic has shifted from SEK 294.60 to SEK 303.80, with analysts pointing to more constructive views on the NLRP3 opportunity set and comparisons to bullish Street research on peers as key drivers behind the updated target assumptions. Analyst Commentary Bullish analysts are drawing parallels between BioArctic's NLRP3 exposure and Street enthusiasm around peers such as BioAge Labs, where recent research has highlighted NLRP3 programs and adjacent cardiovascular and ophthalmology opportunities as a key value driver.ナラティブ更新 • Mar 25
BIOA B: Future Earnings Will Depend On High China Access Risk
Analysts have nudged their fair value estimate for BioArctic to SEK240 from SEK236. This reflects updated assumptions around revenue contraction, profitability and a higher future P/E multiple, while keeping the discount rate broadly similar.ナラティブ更新 • Mar 10
BIOA B: China Alzheimer’s Access And Delivery Shift Will Drive Future Upside
Analysts are keeping their SEK 367.0 price target for BioArctic broadly unchanged, with only modest tweaks to underlying assumptions. They highlight parallels with recent bullish Street research on early stage biotech names that are seeing renewed interest around differentiated clinical assets.ナラティブ更新 • Feb 24
BIOA B: Peer Re-Rating And China Alzheimer’s Momentum Will Reframe Upside
Analysts have raised their BioArctic fair value estimate from SEK353 to SEK367 as they factor in updated views on revenue growth, margins, discount rate and a higher future P/E assumption aligned with recent bullish Street research on comparable biotech names. Analyst Commentary Recent Street research on comparable biotech names has turned more optimistic, with bullish analysts revisiting their models and price targets in light of updated clinical views and perceived market potential.ナラティブ更新 • Feb 09
BIOA B: Future Earnings Will Depend On Risky China Insurance Access
Analysts have raised their fair value estimate for BioArctic from SEK 230 to SEK 236, citing updated assumptions regarding discount rates, revenue growth, profit margins and a slightly higher future P/E multiple. Analyst Commentary Recent analyst work on comparable neurology and biotech names highlights how sensitive valuations can be to small shifts in assumptions around discount rates, revenue build, profitability and terminal P/E multiples.ナラティブ更新 • Jan 25
BIOA B: Future Earnings Will Rely On Risky China Alzheimer Access
Analysts now keep their price target for BioArctic at SEK 230.00, with small adjustments to the discount rate, revenue growth assumptions and future P/E outlook. This reflects only minor changes to their overall view of the company’s risk and profitability profile.ナラティブ更新 • Jan 09
BIOA B: Future Earnings Will Depend On Risky Alzheimer Access Rollout
Analysts have maintained their fair value estimate for BioArctic at SEK 230.00. They have, however, adjusted assumptions related to the discount rate, revenue trends, profit margins, and future P/E to reflect updated views on the company’s risk profile and earnings potential.ナラティブ更新 • Dec 26
BIOA B Future Long Term Margin Upside Will Not Offset Demand Risks
Analysts have modestly raised their price target on BioArctic to SEK 230 (from SEK 230 previously), reflecting slightly lower perceived risk and a substantially improved long term profit margin outlook, despite marginally weaker revenue growth assumptions and a lower projected future P/E multiple. What's in the News Leqembi, developed by BioArctic and Eisai, has been included in China’s new Commercial Insurance Innovative Drug List.ナラティブ更新 • Dec 12
BIOA B: Future Revenue Weakness Will Outweigh Expanding Alzheimer’s Market Approval
Analysts have reduced their price target on BioArctic from SEK 280 to SEK 230. This reflects a more cautious outlook on future revenue growth despite improved profitability expectations and a slightly higher discount rate.分析記事 • Nov 16
BioArctic AB (publ) (STO:BIOA B) Just Released Its Third-Quarter Earnings: Here's What Analysts Think
It's been a pretty great week for BioArctic AB (publ) ( STO:BIOA B ) shareholders, with its shares surging 12% to kr295...ナラティブ更新 • Sep 17
Overhyped Valuations Will Falter Amid Healthcare Headwinds
Despite a significant improvement in BioArctic's net profit margin and a sharp decline in its future P/E multiple, the consensus analyst price target has been revised downward to SEK294.60. What's in the News FDA approved the Biologics License Application for weekly subcutaneous maintenance dosing of lecanemab (LEQEMBI IQLIK) for early Alzheimer's disease; U.S. launch set for October 6, 2025.ナラティブ更新 • Sep 02
Regulatory Approvals And Pipeline Progress Will Redefine Neurodegeneration Care
BioArctic's consensus price target has been reduced to SEK280.50, primarily due to sharply lower revenue growth expectations and a significant drop in the projected future P/E multiple. What's in the News BioArctic entered an option, collaboration, and license agreement with Novartis Pharma involving its proprietary BrainTransporter technology for a potential neurodegeneration treatment, receiving USD 30 million upfront, with up to USD 772 million in potential milestone payments and tiered royalties.分析記事 • Aug 14
Revenues Not Telling The Story For BioArctic AB (publ) (STO:BIOA B) After Shares Rise 26%
OM:BIOA B 1 Year Share Price vs Fair Value Explore BioArctic's Fair Values from the Community and select yours Despite...新しいナラティブ • Jun 01
Regulatory Approvals And Pipeline Progress Will Redefine Neurodegeneration Care
Regulatory approvals and upcoming diagnostics are set to accelerate Leqembi adoption, expanding access and recurring royalty revenues from an underserved and growing patient base.分析記事 • May 29
BioArctic's (STO:BIOA B) Solid Profits Have Weak Fundamentals
BioArctic AB (publ)'s ( STO:BIOA B ) robust earnings report didn't manage to move the market for its stock. Our...分析記事 • May 16
Here's Why BioArctic AB (publ)'s (STO:BIOA B) CEO Compensation Is The Least Of Shareholders Concerns
Key Insights BioArctic will host its Annual General Meeting on 22nd of May CEO Gunilla Osswald's total compensation...分析記事 • Feb 19
Need To Know: Analysts Are Much More Bullish On BioArctic AB (publ) (STO:BIOA B)
Shareholders in BioArctic AB (publ) ( STO:BIOA B ) may be thrilled to learn that the analysts have just delivered a...分析記事 • Feb 18
Earnings Beat: BioArctic AB (publ) (STO:BIOA B) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
It's been a good week for BioArctic AB (publ) ( STO:BIOA B ) shareholders, because the company has just released its...分析記事 • Jan 31
Analysts Just Published A Bright New Outlook For BioArctic AB (publ)'s (STO:BIOA B)
Shareholders in BioArctic AB (publ) ( STO:BIOA B ) may be thrilled to learn that the analysts have just delivered a...分析記事 • Nov 27
Need To Know: Analysts Are Much More Bullish On BioArctic AB (publ) (STO:BIOA B)
Celebrations may be in order for BioArctic AB (publ) ( STO:BIOA B ) shareholders, with the analysts delivering a...分析記事 • Sep 01
BioArctic AB (publ) (STO:BIOA B) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
A week ago, BioArctic AB (publ) ( STO:BIOA B ) came out with a strong set of quarterly numbers that could potentially...分析記事 • Aug 15
Need To Know: The Consensus Just Cut Its BioArctic AB (publ) (STO:BIOA B) Estimates For 2024
The analysts covering BioArctic AB (publ) ( STO:BIOA B ) delivered a dose of negativity to shareholders today, by...分析記事 • Apr 13
Revenues Tell The Story For BioArctic AB (publ) (STO:BIOA B)
With a price-to-sales (or "P/S") ratio of 30.5x BioArctic AB (publ) ( STO:BIOA B ) may be sending very bearish signals...株主還元
| BIOA B | SE Biotechs | SE 市場 | |
|---|---|---|---|
| 7D | -5.8% | -2.7% | 0.05% |
| 1Y | 54.7% | 26.2% | 10.8% |
業界別リターン: BIOA B過去 1 年間で26.2 % の収益を上げたSwedish Biotechs業界を上回りました。
リターン対市場: BIOA B過去 1 年間で10.8 % の収益を上げたSwedish市場を上回りました。
価格変動
| BIOA B volatility | |
|---|---|
| BIOA B Average Weekly Movement | 5.7% |
| Biotechs Industry Average Movement | 9.3% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in SE Market | 12.2% |
| 10% least volatile stocks in SE Market | 3.4% |
安定した株価: BIOA B 、 Swedish市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。
時間の経過による変動: BIOA Bの 週次ボラティリティ ( 6% ) は過去 1 年間安定しています。
会社概要
| 設立 | 従業員 | CEO（最高経営責任者 | ウェブサイト |
|---|---|---|---|
| 2000 | 141 | Gunilla Osswald | www.bioarctic.se |
BioArctic AB (publish)は、スウェーデンで中枢神経系疾患患者向けの生物学的薬剤を開発している。同社は、アンメット・メディカル・ニーズの高い抗体などの革新的な生物学的薬剤の研究開発を行っている。同社の治療領域は、アルツハイマー病、パーキンソン病などの神経変性疾患やその他の中枢神経疾患である。加えて、同社は治療用モノクローナル抗体を開発する技術プラットフォームを保有している。さらに、lecanemab第3相臨床試験、Lecanemabバックアップ第3相臨床試験、BAN1503は探索段階にあり、Exidavnemabは第2相臨床試験、Lecanemabは前臨床試験、BAN2803、BAN2802は前臨床試験、PD-BT2238、ND-BT3814、GD-BT6822は探索段階にある。エーザイおよびアッヴィと共同研究契約を結んでいる。旧社名はBioArctic Neuroscience ABで、2016年にBioArctic AB（publ）に社名変更した。BioArctic AB（publ）は2000年に設立され、スウェーデンのストックホルムを拠点としている。
BioArctic AB (publ) 基礎のまとめ
| BIOA B 基礎統計学 | |
|---|---|
| 時価総額 | SEK 26.63b |
| 収益（TTM） | SEK 213.24m |
| 売上高(TTM) | SEK 1.15b |
124.9x
PER（株価収益率23.2x
P/SレシオBIOA B は割高か？
公正価値と評価分析を参照収益と収入
| BIOA B 損益計算書（TTM） | |
|---|---|
| 収益 | SEK 1.15b |
| 売上原価 | SEK 67.32m |
| 売上総利益 | SEK 1.08b |
| その他の費用 | SEK 866.53m |
| 収益 | SEK 213.24m |
直近の収益報告
Mar 31, 2026
次回決算日
Jul 23, 2026
| 一株当たり利益（EPS） | 2.40 |
| グロス・マージン | 94.13% |
| 純利益率 | 18.59% |
| 有利子負債／自己資本比率 | 0% |
BIOA B の長期的なパフォーマンスは？
過去の実績と比較を見る配当金
0.7%
現在の配当利回り83%
配当性向企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/07/19 13:32 |
| 終値 | 2026/07/17 00:00 |
| 収益 | 2026/03/31 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
このレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
BioArctic AB (publ) 4 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。5
| アナリスト | 機関 |
|---|---|
| Kristofer Liljeberg-Svensson | DNB Carnegie |
| Rajan Sharma | Goldman Sachs |
| Viktor Sundberg | Nordea Markets |